NAMS

SEC source: 0001193125-26-412431 · ownership.xml · derivative · entry 4

Kastelein Johannes Jacob Pieter · CIK 0002000389 · Director · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 344,983

Underlying: Ordinary Shares · 50,246 shares

Expires 2031-07-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price of the option is EUR 1.16392.

F5 · derivative.exercise_date: The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

F6 · ownership.nature: The option was granted to and is held by Futurum through NAP PoolCo B.V. ("PoolCo") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the Issuer.

SEC source: 0001193125-26-412431 · ownership.xml · nonDerivative · entry 2

Kastelein Johannes Jacob Pieter · CIK 0002000389 · Director · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnotes

Disclosed balance after: 69,302

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.10 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

F2 · ownership.nature: These Ordinary Shares are held by Futurum B.V. ("Futurum") through NAP PoolCo B.V. ("PoolCo") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum.

SEC source: 0001193125-26-412431 · ownership.xml · nonDerivative · entry 1

Kastelein Johannes Jacob Pieter · CIK 0002000389 · Director · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnotes

Disclosed balance after: 119,548

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price of the option is EUR 1.16392.

F2 · ownership.nature: These Ordinary Shares are held by Futurum B.V. ("Futurum") through NAP PoolCo B.V. ("PoolCo") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum.

SEC source: 0001193125-26-391985 · ownership.xml · nonDerivative · entry 1

Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 792,923

F1 · balance_after: Includes 163,352 ordinary shares subject to restricted stock unit awards that remain subject to vesting.

F2 · balance_after: Reflects the prior transfer of 608,779 ordinary shares previously reported as indirectly beneficially owned by the Reporting Person. Such ordinary shares were previously held of record by Stichting Administratiekantoor EPNAP for the benefit of the Reporting Person.

SEC source: 0001193125-26-386508 · ownership.xml · nonDerivative · entry 1

Smither John W · CIK 0001559583 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,760

F1 · kind: Reported transaction reflects a sale of ordinary shares to generate proceeds to satisfy the Reporting Person's tax obligations in connection with the prior vesting of restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.24 to $25.37 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

F3 · balance_after: Includes 8,040 ordinary shares subject to restricted stock unit awards that remain subject to vesting.

SEC source: 0001193125-26-381953 · ownership.xml · derivative · entry 2

Gunning Robert William · CIK 0002148571 · Vice President, Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Ordinary Shares · 14,000 shares

Expires 2036-08-31

F2 · derivative.exercise_date: 25% of the shares underlying the option will vest on August 10, 2026, the one-year anniversay of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

SEC source: 0001193125-26-381953 · ownership.xml · nonDerivative · entry 1

Gunning Robert William · CIK 0002148571 · Vice President, Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,200

F1 · shares: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, September 10, 2026, subject to the Reporting Person's continued service through each such date.

SEC source: 0001193125-26-365202 · ownership.xml · derivative · entry 4

Kastelein Johannes Jacob Pieter · CIK 0002000389 · Director · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 395,229

Underlying: Ordinary Shares · 125,000 shares

Expires 2031-07-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price of the option is EUR 1.16392.

F5 · derivative.exercise_date: The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

F6 · ownership.nature: The option was granted to and is held by Futurum through PoolCo for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the Issuer.

SEC source: 0001193125-26-365202 · ownership.xml · nonDerivative · entry 2

Kastelein Johannes Jacob Pieter · CIK 0002000389 · Director · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnotes

Disclosed balance after: 69,302

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.72 to $27.70 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

F2 · ownership.nature: These Ordinary Shares are held by Futurum B.V. ("Futurum") through NAP PoolCo B.V. ("PoolCo") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum.

SEC source: 0001193125-26-365202 · ownership.xml · nonDerivative · entry 1

Kastelein Johannes Jacob Pieter · CIK 0002000389 · Director · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnotes

Disclosed balance after: 194,302

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price of the option is EUR 1.16392.

F2 · ownership.nature: These Ordinary Shares are held by Futurum B.V. ("Futurum") through NAP PoolCo B.V. ("PoolCo") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum.

SEC source: 0001193125-26-312387 · ownership.xml · derivative · entry 7

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,494

Underlying: Ordinary Shares · 80,000 shares

Expires 2034-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The option was granted on January 1, 2024. 25% of the shares underlying the option vested on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

SEC source: 0001193125-26-312387 · ownership.xml · derivative · entry 6

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Ordinary Shares · 25,000 shares

Expires 2033-05-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option was granted on May 18, 2023. 25% of the shares underlying the option vested on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

SEC source: 0001193125-26-312387 · ownership.xml · nonDerivative · entry 5

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,353

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.58 to $31.85 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

F1 · balance_after: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.

SEC source: 0001193125-26-312387 · ownership.xml · nonDerivative · entry 4

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,268

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.58 to $31.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

F1 · balance_after: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.

SEC source: 0001193125-26-312387 · ownership.xml · nonDerivative · entry 3

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,153

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.57 to $30.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

F1 · balance_after: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.

SEC source: 0001193125-26-312387 · ownership.xml · nonDerivative · entry 2

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 129,353

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.

SEC source: 0001193125-26-312387 · ownership.xml · nonDerivative · entry 1

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,353

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.

SEC source: 0001193125-26-281062 · ownership.xml · derivative · entry 6

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Ordinary Shares · 15,000 shares

Expires 2033-05-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option was granted on May 18, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

SEC source: 0001193125-26-281062 · ownership.xml · derivative · entry 5

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,134

Underlying: Ordinary Shares · 25,000 shares

Expires 2033-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

SEC source: 0001193125-26-281062 · ownership.xml · nonDerivative · entry 4

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,353

F2 · balance_after: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.

SEC source: 0001193125-26-281062 · ownership.xml · nonDerivative · entry 3

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,653

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.73 to $30.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

F2 · balance_after: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.

SEC source: 0001193125-26-281062 · ownership.xml · nonDerivative · entry 2

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,353

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-26-281062 · ownership.xml · nonDerivative · entry 1

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,353

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-26-241983 · ownership.xml · derivative · entry 5

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,134

Underlying: Ordinary Shares · 5,000 shares

Expires 2033-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

SEC source: 0001193125-26-241983 · ownership.xml · derivative · entry 4

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 80,015

Underlying: Ordinary Shares · 60,000 shares

Expires 2032-11-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 1, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date.

SEC source: 0001193125-26-241983 · ownership.xml · nonDerivative · entry 3

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,353

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.12 to $36.09 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

F2 · balance_after: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.

SEC source: 0001193125-26-241983 · ownership.xml · nonDerivative · entry 2

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 89,353

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-26-241983 · ownership.xml · nonDerivative · entry 1

Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 84,353

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-26-104239 · ownership.xml · nonDerivative · entry 2

LANGE LOUIS G · CIK 0001238401 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,360

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.13 per share to $31.31 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

SEC source: 0001193125-26-104239 · ownership.xml · nonDerivative · entry 1

LANGE LOUIS G · CIK 0001238401 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,806

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.11 per share to $31.08 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

SEC source: 0001193125-26-099073 · ownership.xml · derivative · entry 9

Kastelein Johannes Jacob Pieter · CIK 0002000389 · Director · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 520,229

Underlying: Ordinary Shares · 101,409 shares

Expires 2031-07-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price of the option is EUR 1.16392.

F6 · derivative.exercise_date: The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

F7 · ownership.nature: The option was granted to and is held by Futurum through NAP PoolCo B.V. ("PoolCo") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the Issuer.

SEC source: 0001193125-26-099073 · ownership.xml · nonDerivative · entry 6

Kastelein Johannes Jacob Pieter · CIK 0002000389 · Director · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 69,302

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 per share to $30.80 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

F2 · ownership.nature: The Ordinary Shares are held by Futurum B.V. ("Futurum") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum.

SEC source: 0001193125-26-099073 · ownership.xml · nonDerivative · entry 5

Kastelein Johannes Jacob Pieter · CIK 0002000389 · Director · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 170,711

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price of the option is EUR 1.16392.

F2 · ownership.nature: The Ordinary Shares are held by Futurum B.V. ("Futurum") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum.

SEC source: 0001193125-26-100798 · ownership.xml · derivative · entry 3

LANGE LOUIS G · CIK 0001238401 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 44,619 shares

Expires 2027-11-23

SEC source: 0001193125-26-100798 · ownership.xml · nonDerivative · entry 2

LANGE LOUIS G · CIK 0001238401 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,979

SEC source: 0001193125-26-099073 · ownership.xml · derivative · entry 8

Kastelein Johannes Jacob Pieter · CIK 0002000389 · Director · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 621,638

Underlying: Ordinary Shares · 94,124 shares

Expires 2031-07-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price of the option is EUR 1.16392.

F6 · derivative.exercise_date: The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

F7 · ownership.nature: The option was granted to and is held by Futurum through NAP PoolCo B.V. ("PoolCo") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the Issuer.

SEC source: 0001193125-26-099073 · ownership.xml · nonDerivative · entry 4

Kastelein Johannes Jacob Pieter · CIK 0002000389 · Director · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 69,302

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 per share to $30.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

F2 · ownership.nature: The Ordinary Shares are held by Futurum B.V. ("Futurum") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum.

SEC source: 0001193125-26-099073 · ownership.xml · nonDerivative · entry 3

Kastelein Johannes Jacob Pieter · CIK 0002000389 · Director · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 163,426

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price of the option is EUR 1.16392.

F2 · ownership.nature: The Ordinary Shares are held by Futurum B.V. ("Futurum") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum.

SEC source: 0001193125-26-100798 · ownership.xml · nonDerivative · entry 1

LANGE LOUIS G · CIK 0001238401 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.03 per share to $29.68 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

F2 · ownership.nature: The shares are held directly by LGLange III Trust DTD10 (the "Trust") for the benefit of the Reporting Person.

SEC source: 0001193125-26-099073 · ownership.xml · derivative · entry 7

Kastelein Johannes Jacob Pieter · CIK 0002000389 · Director · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 715,762

Underlying: Ordinary Shares · 104,467 shares

Expires 2031-07-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price of the option is EUR 1.16392.

F6 · derivative.exercise_date: The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

F7 · ownership.nature: The option was granted to and is held by Futurum through NAP PoolCo B.V. ("PoolCo") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the Issuer.

SEC source: 0001193125-26-099073 · ownership.xml · nonDerivative · entry 2

Kastelein Johannes Jacob Pieter · CIK 0002000389 · Director · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 69,302

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 per share to $30.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

F2 · ownership.nature: The Ordinary Shares are held by Futurum B.V. ("Futurum") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum.

SEC source: 0001193125-26-099073 · ownership.xml · nonDerivative · entry 1

Kastelein Johannes Jacob Pieter · CIK 0002000389 · Director · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 173,769

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price of the option is EUR 1.16392.

F2 · ownership.nature: The Ordinary Shares are held by Futurum B.V. ("Futurum") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum.

SEC source: 0001193125-26-085947 · ownership.xml · derivative · entry 3

Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 239,267

Underlying: Ordinary Shares · 443,707 shares

Expires 2031-07-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price of the option is EUR 1.16392.

F2 · derivative.exercise_date: The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

SEC source: 0001193125-26-085947 · ownership.xml · nonDerivative · entry 2

Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,144

SEC source: 0001193125-26-085947 · ownership.xml · nonDerivative · entry 1

Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 617,851

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price of the option is EUR 1.16392.

SEC source: 0001193125-26-078718 · ownership.xml · derivative · entry 14

Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 682,974

Underlying: Ordinary Shares · 183,332 shares

Expires 2031-07-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price of the option is EUR 1.16392.

F10 · derivative.exercise_date: The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

SEC source: 0001193125-26-078718 · ownership.xml · nonDerivative · entry 10

Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 174,144

F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.35 to $34.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

F9 · balance_after: The amount reported in Column 5 reflects the transfer of 285,715 ordinary shares from the Reporting Person to the Michael H. Davidson 2026 Grantor Retained Annuity Trust (the "GRAT") on February 26, 2026, which transfer was exempt from Section 16 pursuant to Rule 16a-13 under the Securities Exchange Act of 1934. The Reporting Person is the sole annuitant and trustee of the GRAT.

SEC source: 0001193125-26-078718 · ownership.xml · nonDerivative · entry 9

Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 477,783

F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.34 to $34.33 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

SEC source: 0001193125-26-078718 · ownership.xml · nonDerivative · entry 8

Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 643,191

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price of the option is EUR 1.16392.

SEC source: 0001193125-26-078718 · ownership.xml · derivative · entry 13

Davidson Michael H. · CIK 0001573785 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 866,306

Underlying: Ordinary Shares · 58,253 shares

Expires 2031-07-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price of the option is EUR 1.16392.

F10 · derivative.exercise_date: The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.